This Article  • References  • Full text PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citation map  • Citing articles on HighWire  • Contact me when this article is cited  Related Content  • Similar articles in JAMA  Social Bookmarking   What's this?

Implications of the Results of Recent Clinical Trials

Nemat O. Borhani, MD

JAMA. 1985;254(2):257-262.

	Since this article does not have an abstract, we have provided the first 150 words of the full text PDF and any section headings.

IDEALLY, coronary heart disease should be prevented before it becomes clinically manifest, but when primary prevention fails, prevention of death and recurrent myocardial infarction after the first event, or secondary prevention, is still a worthwhile and achievable goal. Therefore, a review of the results of recent clinical trials on both secondary and primary prevention of coronary heart disease, and of their implications for clinical practice, would seem to be timely and useful.

SECONDARY PREVENTION OF CORONARY HEART DISEASE

A previous history of myocardial infarction is a recognized risk factor for recurrent events, including sudden death. This review reports on recent clinical trials on the efficacy of platelet-active drugs, β-adrenergic blockers, and lowering blood cholesterol regimen in treatment of this high-risk group of patients. Only selected examples of large-scale clinical trials, both short and long term, are addressed.

Clinical Trials on the Protective Effect of Platelet-Active Drugs

Platelet-active drugs, such as . . . [Full Text PDF of this Article]

Author Affiliations
From the Department of Community Health, School of Medicine, University of California at Davis.

Footnotes
This article is one of a series sponsored by the American Heart Association.

Reprint requests to Department of Community Health, School of Medicine, University of California at Davis, Davis, CA 95616 (Dr Borhani).

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?